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Degenerative diseaseHigh hydrostatic pressure (HHP) is a valuable tool to study processes such as protein folding, protein hydra-
tion and protein–protein interactions. HHP is a nondestructive technique because it reversibly affects inter-
nal cavities excluded from the solvent present in the hydrophobic core of proteins. HHP allows the solvation
of buried amino acid side chains, thus shifting the equilibrium towards states of the studied molecule or
molecular ensemble that occupy smaller volumes. HHP has long been used to dissociate multimeric pro-
teins and protein aggregates and allows investigation of intermediate folding states, some of which are
formed by proteins involved in human degenerative diseases, such as spongiform encephalopathies and
Parkinson's disease, as well as cancer. When coupled with nuclear magnetic resonance and spectroscopic
methods such as infrared and ﬂuorescence spectroscopy, HHP treatment facilitates the understanding of
protein folding and misfolding processes; the latter is related to protein aggregation into amyloid or amor-
phous species. In this review, we will address how HHP provides information about intermediate foldingte; α-syn, alpha-synuclein; bis-ANS, 4, 4′-bis(1-anilinonaphthalene 8-sulfonate); DA, dopamine; FTIR, Fourier transform
mediate state; LB, Lewy bodies; NMR, nuclear magnetic resonance; p53, p53 tumor suppressor protein; PD, Parkinson's
tein; TEM, transmission electron microscopy; TTR, transthyretin.
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10 Y. Cordeiro et al. / Biophysical Chemistry 183 (2013) 9–18states and the aggregation processes of p53, which is related to cancer, and prion proteins, transthyretin
and α-synuclein, which are related to human degenerative diseases.
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Pressure is a thermodynamic variable with longstanding successful
biological applications [reviewed in 1–5]. However, the full potential
of high-pressure methods has not been assessed. The seminal article
by Bridgman in 1914 [6], in which he observed the pressure-mediated
denaturation of ovalbumin, introduced the promising properties of
the pressure approach. In the last 50 years, several groups have used
pressure to explore protein denaturation, dissociation, and conforma-
tional changes [see reviews: 1–3,7–9].
The advantage of using pressure to observe the equilibrium of pro-
tein conformation is the simplicity of the data analysis. For a given
change produced by pressure in a protein P,
P⇆P′;
and pressure will drive the equilibrium according to the formula:
dΔG Tð Þ=dp ¼ ΔV Tð Þ; ð1Þ
where ΔV represents the difference between the volumes occupied
by the solvated products (P′) and reactants (P). The equilibrium con-
stant K(p) can be expressed by
d lnK pð Þ=dp ¼−ΔV pð Þ=RT: ð2Þ
HHP has provided promising results on protein denaturation and
dissociation, as well as the folding and stability of protein–DNA
complexes, virus particles and amorphous and ﬁbrillar aggregates
[1,2,10,11]. Pressure changes the equilibrium in the direction of
the species that occupies the lower molar volume. Because of the
large number of atoms involved, packing defects cannot be avoided,
and these defects lead to formation of cavities and void volumes in-
side the native fold that render proteins susceptible to HHP [12,13].
2. Squeezing amyloid ﬁbrils
One of the most challenging questions in biology is how proteins
ﬁnd their unique set of native-state conformations based only on the in-
formation coded by their primary sequences (self-assembly) [14,15].
Incompletely folded chains that form en route expose regions that are
buried in the native state [16–18]. Such species are prone to inappropri-
ate contacts with neighboring molecules, giving rise to protein aggre-
gates that exert their effects either by a “loss of function” (lack of
active protein) or by a “toxic gain of function” (cytotoxicity of aggre-
gates) [reviewed in: 19]. Living systems have evolved elaborate strate-
gies to minimize this problem, including molecular chaperones andfolding catalysts, as well as a stringent “quality control” mechanism
that operates in the ER and a “clearance machine” for protein degra-
dation (the ubiquitin–proteasome system) [20,21]. Unfortunately,
despite these “housekeeping” strategies, under certain circum-
stances (e.g., stress, protein turnover, natural protein unfolding in-
side cells, and aging), aggregation occurs and can cause disease
[22,23]. In amyloidogenic diseases, aggregates have a common orga-
nized architecture, known as the amyloid ﬁbril [reviewed in: 18].
Alzheimer's disease, Parkinson's disease and approximately 40
other misfolding disorders are examples of these diseases. The amy-
loid ﬁbril has a cross-β fold [24]. Recently, some atomic structures of
amyloid ﬁbrils have been solved [25–27]. There is abundant evidence
that the interface formed by the contact between two β-sheets in the
ﬁbril is dry (lacking water molecules), while the outer faces are wet.
The ability to form amyloid ﬁbrils is not restricted to proteins in-
volved in amyloidogenic diseases, but it seems to be a general pro-
pensity of all polypeptide chains [28]. In most cases, protein
aggregation proceeds when a transient intermediate (I) conforma-
tion builds up during folding or unfolding. The accepted idea
concerning the tendency of the I state to aggregate is based on its
low solubility due to the presence of a large, hydrophobic surface
that is still exposed to the aqueous environment [29]. This surface
creates conditions for inter- and intra-subunit contacts. These spe-
cies are formed under certain stress conditions during the unfolding
or processing of a protein, either in a cellular compartment or in the
extracellular space [30].
In vitro, chemical or physical tools are used to study these partially
folded conformations and allow their structural characterization. High
hydrostatic pressure (HHP) is a powerful method to trap such confor-
mations [4]. Partially folded conformations aremore “open” structures
(fewer solvent-excluded cavities, lower molar volume), which might
explain why they are favored under high pressure. In fact, intermedi-
ate states are not stabilized by pressure, they are just less destabilized
than folded states; therefore, under pressure, I states are only relatively
more stable than the native state (allowing them to be studied by ap-
plying HHP). HHP leads generally to a decrease in the length of
H-bonds, but not their rupture, which explains why at least some
of the protein secondary structure can be preserved under pressure.
Some amyloid ﬁbrils seem to present cavity defects because
they are dissociated by relatively low pressure [31–37]. However,
mature amyloids in general possess a strong hydrogen bonding
network that maintains the ﬁbrils tightly packed, reducing their
susceptibility to HHP. Amyloid ﬁbril formation evolves through
the population of species with different packing, morphology,
number of subunits, and H-bonding stabilization. Therefore, it is
reasonable to visualize HHP as a tool that allows differentiating
Fig. 1.NMR structures of mammalian prion proteins and charge distribution in the pro-
tein surface. A, Superposition of the globular domains of recombinant PrP from cattle
(1DX0.pdb) (red), mouse (1AG2.pdb) (green), human (1QLX.pdb) (blue), and Syrian
hamster (1B10.pdb) (yellow). Figure was prepared with PyMOL. B, (1) human PrP,
1QM1.pdb; (2) cattle PrP, 1DWZ.pdb; (3) mouse PrP, 1XYX.pdb; (4) Syrian hamster
PrP, 1B10.pdb; (5) rabbit PrP, 2FJ3.pdb. Left: Ribbon representations of the secondary
and tertiary structures of the PrPs. Right: Distributions of electrostatic potentials
(blue: positive charges; red: negative charges).
Modiﬁed from reference [46].
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tions that stabilize such intermediate states that occur along the
formation of a mature ﬁbril. Spectroscopic properties that can be
measured under pressure (e.g., ﬂuorescence, absorption, FTIR,
Raman, NMR) can provide details of partially folded states. As will
be further reviewed here, the use of HHP with spectroscopic and
structural tools has allowed the dissection of the role of packing
and cavities in protein misfolding and aggregation.
Herein, we will concentrate on four amyloidogenic proteins: 1) prion
protein (PrP), which is involved in transmissible spongiform en-
cephalopathies (TSEs); 2) tumor suppressor protein p53, which is re-
lated to cancer; 3) transthyretin (TTR), which is involved in senile
systemic amyloidosis (the wild-type protein), cardiomyopathy, central
nervous system deposits and familial amyloidotic polyneuropathy
(caused by more than 90 TTR variants); and 4) α-synuclein (α-syn),
which is associated with Parkinson's disease (both wild-type and
variants).
3. HHP and PrP: insights into structural conversion, stability
and aggregation
PrP is a partially unfolded protein that is involved in neurodegener-
ative diseases, and its conformation and stability have been widely in-
vestigated in the past 30 years. The importance of PrP as the main
agent responsible for TSEs is unquestioned [38,39], although othermol-
ecules, such as glycosaminoglycans, lipids and nucleic acids, have been
implicated in the conversion of normal cellular PrP into an abnormal
conformation, named PrPSc [40–42]. The conversion of PrPC into PrPSc
involves the acquisition of a higher β-sheet content in the latter form,
and diminishes PrP solubility in aqueous solvents [43]. To understand
the conversion process and why, once formed, PrPSc triggers the
misfolding of native PrP present in the affected organism, a set of bio-
physical data was obtained on the stability of PrP. The PrP primary se-
quence is formed by 209 amino acid residues, and native PrP has two
structurally distinct domains: an N-terminal ﬂexible region (residues
23 to ~125) and an α-helical C-terminal globular domain (~125 to
231) [44], that are highly conserved among different species [45]
(Fig. 1A). One of the properties that distinguishes PrPs from different
species is the charge distribution on the protein surface (Fig. 1B) [46].
Charge distribution and cavities likely affect stability under conditions
of hydrostatic pressure. The cross-talk between these different PrP do-
mains also warrants investigation because conversion into PrPSc is
reﬂected by secondary structure changes, mainly in the N-terminal
region (residues 90 to ~140) [47] but can also affect the C-terminal do-
main [48,49]. Most of the biophysical data were collected with different
recombinant mammalian PrPs, either mature full-length PrPs, compris-
ing residues 23–231 or 23–230 or truncated versions of PrP, mainly
containing the globular C-terminal domain. Herein, we will focus on
the application of HHP combined or not combined with high tempera-
ture on native and aggregated recombinant PrP (rPrP) forms and how
these results contribute to our understanding of PrP stability and the
generation of scrapie-like conformations.
Incubation of rPrP at temperatures above 40 °C leads to PrP
unfolding and aggregation into amorphous species [9,35,50]. These
aggregates have increased β-sheet content as revealed by Fourier
transform infrared (FTIR) spectroscopy [35,50]. HHP was applied to
dissociate temperature-induced aggregates of Syrian hamster rPrP
(globular domain, residues 90–231) [50] and full-length murine
rPrP [35] (Fig. 2). Dissociation curves provide us with the thermody-
namic parameters for β-sheet-rich PrP unfolding, which is an alter-
native conformation of PrP that is possibly related to PrPSc (at least
in secondary structure content). Pressure jumps were applied to
thermal-aggregated Syrian hamster PrP (ShaPrP), and pressure
values of ~2 kbar were sufﬁcient to maintain ShaPrP in the native
state, even at temperatures >70 °C [50]. This approach was also ap-
plied to amyloid ﬁbrils of hen lysozyme that was deﬁcient in disulﬁdebonds and thus prone to aggregation [51]. Rapid pressure increase
(~1 min) up to 2 kbar dissociated preformed ﬁbrils into monomers;
this process was fully reversible [51]. Such thermal-induced aggregates
are not densely packed because they are susceptible to dissociation by
relatively mild HHP values (~2 kbar). Moreover, these aggregates
bind the ﬂuorescent probes 1-anilino 8-naphthalene sulfonate (ANS)
and 4,4′-bis(1-anilinonaphthalene 8-sulfonate) (bis-ANS), which inter-
act with protein cavities and do not bind to completely unfolded or
packed species [52–54]. The formation of rPrP aggregated species is ki-
netically driven as the conformation and packing of these aggregates
change over time. When rPrP23–231 is incubated at 50 °C for 48 h,
Fig. 2. Pressure effects on murine full-length rPrP (rPrP23–231) after different treat-
ments, investigated by HHP-FTIR. Pressure susceptibility of rPrP aggregated at 50 °C
for 48 h (A) or 2 h (B), and native rPrP at 25 °C (C). Secondary structure components
are shown after deconvolution and peak ﬁtting of the amide I region of FTIR spectra.
Figure adapted from [35].
Table 1
Thermodynamic parameters calculated from pressure studies with different prion
protein constructions.
Protein model Temp. (°C) ΔG (kcal/mol) ΔV (ml/mol) Reference
mPrP23–231
(native)
25 5.37 ± 0.15 −29 [35]
mPrP23–231
(β-sheet, aggregated)
50 2.81 ± 0.10 −43.6 ± 7 [35]
ShaPrP90–231
(non-aggregated)
40 0.94a −31.9 ± 1.9 [50]
huPrP121–230
(native)
20 4.44 ± 0.69b −125 ± 32b [56]
ShaPrP90–231
(native)
30 5.54 ± 0.84b N.D. [57]
mPrP23–231
(amyloid ﬁbril)
25 8.86 ± 0.31c −18.3 ± 1.7c [37]
mPrP23–231
(amyloid ﬁbril)
25 9.63 ± 0.31d −23.8 ± 1.8d [37]
All ΔG values were calculated assuming two state transitions. aΔGU2.0 kbar, 40 °C; bfree
energy and volume changes calculated from transition of native to intermediate states
of PrPs. Free energy and volume changes obtained for the fastc and slowd phases of
mPrP amyloid ﬁbril dissociation by fast pressure increase to 6 kbar; N.D., not determined.
12 Y. Cordeiro et al. / Biophysical Chemistry 183 (2013) 9–18the resultant oligomer is uncompressible, even at 12 kbar [35]
(Fig. 2A), while incubation at the same temperature for 2 h resulted
in pressure-sensitive aggregates (Fig. 2B). This result suggests thereorganization of aggregates and the loss of internal cavities over
time.
HHP-FTIR was used to follow secondary structure changes in
full-length murine rPrP (rPrP23–231) and in truncations lacking
portions of the N-terminal domain [35,55]. This approach allows an
appreciation of the role of the ﬂexible N-terminal domain in stability
under HHP conditions and in the aggregation of rPrP induced by HHP
and temperature. FTIR analysis revealed that although the rPrP glob-
ular domain is highly stable under pressure, this protein is partially
unfolded above 5 kbar, with a loss of α-helices accompanied by an
increase in random coils and turns [35] (Fig. 2C). The reversibility
of this effect allows the calculation of the thermodynamic parame-
ters of unfolding (Table 1). HHP-FTIR measurements revealed that
temperature-induced rPrP β-sheet aggregates (scrapie-like) are
less stable than a native α-helical rPrP [35] (Fig. 2). Moreover, this
stability seems to depend on the presence of the N-terminal domain,
as rPrP variants lacking the octarepeat region (residues 50–91) and
residues 32–121 are more prone to aggregation after pressurization
than full-length rPrP [55]. Another report showed that rPrP aggre-
gates as amyloid ﬁbrils after pressure treatment, even without the
N-terminal domain [53]. Protoﬁbrils and globular aggregates that
are resistant to proteinase K (PK) treatment form after a return to at-
mospheric pressure and are characterized by thioﬂavin T (ThioT)
binding [53]. The time of pressurization is important to deﬁne the ag-
gregate morphology because amyloid ﬁbrils form after only over-
night incubation at 6 kbar [53].
Although we veriﬁed that the N-terminal domain increases rPrP
stability against HHP-induced unfolding [55], the importance of the
N-terminal region of rPrP in driving aggregation and in overall rPrP
stability remains controversial. The combined use of pressure, tem-
perature and pH can aid in our understanding of the importance of
each PrP domain in protein aggregation and conformational conver-
sion. Additionally, the presence of different folding intermediates
that may be populated in vivo can be revealed. High-pressure NMR
studies on the full-length and globular domain (121–230) truncated
variant of human rPrP (huPrP) showed that HHP could reveal struc-
turally similar folding intermediates for both variants [56]. In this
case, the N-terminal region did not dictate a propensity for confor-
mational change, but transient interactions of C-terminal residues
with the ﬂexible domain were identiﬁed [56]. As expected (Fig. 1),
similar conformational states for the globular domains of huPrP
and ShaPrP were revealed by HHP coupled with NMR analysis, with
the identiﬁcation of two intermediate states for each protein [57].
However, speciﬁc residues in huPrP and ShaPrP display different re-
sponses to pressure (up to 2.5 kbar), yielding different ΔG0 values
13Y. Cordeiro et al. / Biophysical Chemistry 183 (2013) 9–18[57] (Fig. 3). These small but signiﬁcant differences might be related
to the prion species barrier. HHP populates excited protein states
that can be detected by NMR, even if they only represent a minor
fraction of the total protein conformation in solution. Following
pressure-induced chemical shift variations, one can identify conforma-
tional changes in every amino acid residue from the studied protein. A
metastable intermediate state of ShaPrP90–231 was identiﬁed by 2D
NMR coupledwith pressure variation at low pH [58]. Although it repre-
sents only a small fraction of the total ShaPrP in solution, this interme-
diate state might be a precursor to PrP amyloidogenesis.
HHP treatment can dissociate preformed temperature-induced
aggregates [9]. However, HHP can also induce protein aggregation,
as it can stabilize misfolded intermediate species (in relation to the
native conformation) that are prone to aggregation. These species
can aggregate even under HHP or after decompression to atmo-
spheric pressure [9,59]. Transmission electron microscopy (TEM)
and spectroscopic analysis of pressure-induced PrP aggregates
showed that, depending on the pressure applied, pH values and
time of pressurization, different supramolecular structures are pop-
ulated [54]. Pressurization at 6.0 and 4.7 kbar at basic and neutral
pH induces the formation of aggregated (AggHP) and intermediate
(IHP) species, respectively, of full-length murine rPrP [54]. Immedi-
ate return to atmospheric pressure leads to the conversion of AggHP
into amorphous aggregates and recovers native rPrP for IHP. If pres-
sure is maintained for a longer period (0.75 d for AggHP and 8 d for
IHP), spherical and ﬁbrillar aggregates form, suggesting different ag-
gregation pathways for this protein that are kinetically driven and
dependent on the sample environment. ANS binds mainly to the
amorphous aggregates, with increased ﬂuorescence emission com-
pared to ﬁbrillar and spherical aggregates and the native protein
[54]; thus, packing differences for pressure-induced aggregates are
evident. It remains to be established whether these aggregated spe-
cies present different toxicity levels to cells that are susceptible to
prion infection. Similarly, HHP and pressure jumps were applied to
toxic amyloid ﬁbrils ofmurine rPrP, resulting in irreversible disaggrega-
tion and reduced toxicity to primary neuronal cells [37]. The kinetics of
amyloid ﬁbril dissociation was followed by thioﬂavin T binding, and
thermodynamic activation parameters were obtained. Both activa-
tion entropy and enthalpy seemed to control the reaction kinetics in-
duced by pressure, and a high-energy barrier was responsible for the
high stability of amyloid ﬁbrils to pressure [37]. In Table 1 we list theFig. 3. Different HHP susceptibilities of speciﬁc residues of mammalian prion proteins. ΔG0
(121–231) of human (huPrP) and hamster (ShaPrP) prion proteins. Free energy values were
L2, α-helix 1, the second half of α-helix 2, and α-helix 3.
Adapted from [57].thermodynamic parameters obtained for different PrP constructions
under HHP and/or temperature treatment.
Another application of HHP is to diminish prion infectivity in brain
or food samples. HHP coupledwith high temperature reduces the infec-
tivity of the 263K prion strain and renders PrPSc extracted from infected
brains susceptible to PK digestion [60]. Additionally, treatment of sau-
sages spiked with the same prion strain with HHP at 12 kbar and
135 °C reduces prion infectivity (measured as LD50) by a factor of 106
[61].
In general, pressure treatment changes the physicochemical nature
of PrP and other proteins. As the native state is less pressure-stable
than partially folded states, HHP allows to trap different I states that,
upon decompression, can aggregate into distinct species with different
packing and morphologies. HHP has provided quantitative information
about the stability of different mammalian PrPs (Table 1) and has
helped to reveal PrP misfolded intermediates, dissociate preformed ag-
gregates, reduce prion infectivity in biological samples and trigger PrP
aggregation into potential scrapie-like forms or precursors.
4. Cancer, amyloid, and p53
p53 is involved in cell cycle control, and its malfunction contributes
to diverse types of cancer [62,63]. This protein is organized as a tetra-
mer, each subunit composed of a central DNA-binding domain, an
N-terminal region responsible for transcriptional activation and a
C-terminal domain that maintains tetramerization [64]. p53 binds sev-
eral protein targets [62] in the cell, and bothwild-type p53 and hot-spot
mutants can aggregate in vitro and in vivo [62,65–73]. Some of these
p53 aggregates possess an amyloid nature [66,69–71,73], suggesting
that cancer might share some similarities with protein conformational
diseases.
When incubated at temperatures above 37 °C, the central domain of
WT p53 (p53C) and of a p53 hot-spot mutant (R248Q) undergoes
unfolding and oligomerization, as veriﬁed by light scattering and intrinsic
ﬂuorescence [65,66]. HHP treatment (up to ~3 kbar) at 37 °C, also leads
into p53 aggregation, but the morphologies of temperature-induced and
pressure-induced aggregates are signiﬁcantly different [66,74]. While
high temperature treatment induces the predominant formation of amor-
phous aggregates, HHP generates annular aggregates and amyloid-like ﬁ-
brils, as observed by atomic force microscopy, TEM and ThioT binding
[66]. The morphology of the aggregates changes with time after a returnvalues at atmospheric pressure obtained after HHP treatment of the globular domains
calculated for individual residues. Depicted residues are distributed mainly along loop
14 Y. Cordeiro et al. / Biophysical Chemistry 183 (2013) 9–18to atmospheric pressure, as ﬁbrillar aggregates are only visualized
~1 month after decompression [66]. Ishimaru et al. [66] used HHP
as a mild tool at neutral pH to obtain ordered aggregation of WT or
R248Q p53C. The formation of amyloid-like ﬁbrils suggested that
cancer could be caused by misfolded p53 that is sequestered into
high-molecular-weight aggregates, thus losing its function. Investi-
gation of the same p53C constructs at low pH (5.0) revealed that
they adopt a molten globule conformation with a residual secondary
structure content and higher hydrodynamic radius compared to
their native counterparts (pH 7.2) [75,76]. Both WT p53C and
R248Q p53C are less stable under pressure treatment at pH 5.0
than at pH 7.2, indicating that a reduction in pH, as occurs in tumor
environments [77], favors its loss of function. X-ray diffraction anal-
ysis, Thio-T binding, Congo red binding and TEM conﬁrmed that olig-
omeric species and amyloid ﬁbrils of p53 form after pressure (Fig. 4)
and temperature treatment at pH 7.2 [71]. These aggregates are toxic
to mammalian cells in culture, and aggregated R248Q p53C seeds
wild-type p53 aggregation [71], characteristics that are typical of
prions. The initial pressure studies showing the amyloid character
of p53 aggregation resulted in studies to test whether mutant p53
would act as a prion [66,68,71]. The prion-like behavior of oncogenic
p53 mutants provides an explanation for their negative dominance
effect and indicates that they may serve as a potential target for can-
cer therapy [71].
We also found that protein binding to a consensus DNA sequence
increases p53C stability under pressure conditions and prevents the
formation of the misfolded conformation, an effect that is related to
the DNA-binding afﬁnity [67]. Interference with the DNA-binding af-
ﬁnity by altering the ionic strength either increases or completely
abolishes the observed stability of the protein. The ﬁnding that
full-length p53 is dramatically stabilized by the binding of a cognateFig. 4. HHP-induced aggregation of WT and R248Q p53 central domains. A, ThioT ﬂuoresce
R248Q (triangle) p53C (5 μM) at pH 7.2. B, X-ray diffraction spectrum of R248Q p53C after
p53C at pH 7.2 and pH 5.0. HP aggregates were formed by incubation of samples at 5 μM w
Figure adapted from [71].sequence is of particular biological and medical interest. This in-
crease in DNA-mediated protein stability might be relevant for ther-
apeutic approaches based on strategies for the rescue of misfolded
wild-type p53C or denatured p53C mutants. Additionally, cognate
DNA is capable of rescuing most of the native conformation of a
misfolded protein [67].
In summary, HHP and temperature treatments have been used to
change the conformation of p53 into different aggregates and molten
globule states.
5. TTR
TTR is a homotetrameric protein that carries retinol binding protein
and thyroxin in the plasma [78,79]. Misfolding and aggregation of both
wild-type and mutants of TTR cause human amyloidogenic diseases,
such as senile systemic amyloidosis for wild-type TTR and familial
amyloidotic polyneuropathy (FAP) and familial amyloidotic cardiomy-
opathy for unstable TTR mutants [79–81].
Treatment of TTR with high pressure leads to partially unfolded
monomers; upon a decrease in pressure, altered tetramers form with
weaker subunit interactions and amyloidogenic properties [31–33].
These altered monomers and tetramers have been studied using ﬂuores-
cent dyes at equilibrium. At high pressure, the tryptophan ﬂuorescence
emission of TTR exhibits a large red shift, indicating substantial denatur-
ation, but the protein can still bind bis-ANS, suggesting the persistence
of tertiary contacts [31]. The most surprising result from these studies
was the observation of ﬁbril formation immediately after decompression
in relativelymild pH and temperature conditions (pH 5.0; 37 °C; 1–3 μM
TTR) (Fig. 5A). The thermodynamic stability of wild-type TTR has been
compared with that of aggressive amyloidogenic mutants (L55P
and V30M) and with the non-amyloidogenic mutant T119M [32].nce emission area (50 μM) as a function of the pressure increase for WT (diamond) or
HHP-induced aggregation at pH 7.2. C, TEM images of HP aggregates of WT and R248Q
ith pressures up to 3 kbar at 37 °C.
Fig. 5. HHP effects on TTR: population of an altered tetramer prone to aggregation. A,
wild-type and mutant TTR [(■) T119M, 5 μM, pH 3.7; (●) wt, (♦) V30M; (▲) L55P]
subjected to 3 kbar for ∼60 min at 37 °C, pH 5.6. Light-scattering (LS) was measured
after pressure release (relative LS values are shown). Inset: aggressive mutant, (△) L55P
was incubated at pH 5.6 at 1 atm and LS was recorded; (▲) curve obtained after pressure
release (panel obtained from reference [32]). B, Free-energy diagram for TTR dissociation,
unfolding, and aggregation. Circles: native tetramer andmonomer; squares: altered tetra-
mer, monomer, and aggregates; line: denatured, unfolded monomer.
Modiﬁed from reference [31].
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where L55P is the least stable variant and has the highest propensity for
ﬁbrillogenesis [32] (Fig. 5A).
The oligomeric state of TTR that gives rise to these ﬁbrils is a
“loose” tetramer that is found in equilibrium with a small fraction of
monomers, as visualized by gel-ﬁltration chromatography [31]. This
altered tetramer, called T4⁎ (pre-aggregated state), is in equilibrium
with the monomeric species, which is also able to aggregate into
ﬁbrils. The T4⁎ state appears to be physiologically relevant for two
reasons: it seeds aggregation, and it can act as a reservoir of altered
monomers that might rapidly aggregate (Fig. 5B). The T4⁎ state could
be prevented to aggregate by keeping it at low temperature (4 °C).
In this respect, amyloid aggregation reaction is very similar to other
association reactions such as virus assembly [82].
Another potential use of HHP is for drug screening. Because TTR
and other amyloidogenic proteins aggregate within a few minutesafter decompression (~30 min), in a single day it is possible to scan
several compounds with the potential to inhibit ﬁbril formation
[33,83]. In the case of TTR, this represents an enormous improvement
because under optimal conditions at atmospheric pressure, TTR ag-
gregation takes 72 h to complete.
More recently, HHP has been employed to explore potential ther-
apeutic strategies against TTR amyloidogenic diseases by trapping
the monomer of a non-amyloidogenic variant of TTR [84]. The com-
bination of HHP with cold temperature and low urea concentration
produced long-lived monomers of the non-amyloidogenic mutant
T119M. When they were mixed with aggressive TTR mutants,
non-amyloidogenic heterotetramers were generated [84]. These re-
sults underscore the potential of HHP to help us understand and
treat amyloidogenic diseases.
6. Pressure studies on α-synuclein
Parkinson's disease (PD) is one of the major neurodegenerative dis-
orders of middle and old age; it is characterized by muscle rigidity,
tremor and bradykinesia, with dementia occurring in a minority of pa-
tients [85,86]. The main pathological hallmarks of PD are characteristic
inclusions called Lewy bodies (LB) that occur in the cytoplasm of neu-
rons, predominantly in the substantia nigra [86–88]. The major compo-
nent of LB is α-syn, a soluble unfolded protein that can aggregate into
insoluble amyloid ﬁbrils that then form LB, followed by ubiquitination
and accumulation of neuroﬁlaments [86,87]. The healthy neurons in
PD patients are the ones that accumulate LB; this ﬁnding has led re-
searchers to question whether LB are the cause of the symptoms of PD
or a cellular strategy to eliminateα-syn and other neurotoxicmolecules
[85–87,89]. Naturalmutants ofα-syn (A53T and A30P) have been iden-
tiﬁed in families with early onset PD [90,91]. However, the causes of ag-
gregation of α-syn in sporadic forms of PD remain as open questions.
The loss of neurons in the substantia nigra results in dopamine (DA)
dysfunction, and the current therapy for PD is based on L-DOPA replace-
ment [88].
In vitro aggregation of wt, A53T and A30P α-syn is a slow process
and leads to ﬁbrils with similar morphologies [89]. The A53T mutation
accelerates aggregation, but the effects of the A30P mutation are
unclear; it appears to accelerate the formation of non-ﬁbrillar oligo-
mers, which are assumed to represent pre-ﬁbrillar intermediates [89].
Future strategies to design drugs against PD will be based on the possi-
ble neurotoxic effects of these pre-ﬁbrils. We investigated the stability
under high pressure of α-syn and TTR ﬁbrils (Fig. 6); our most impor-
tant ﬁndings were two-fold: i) amyloid ﬁbrils are sensitive to HHP
and are dissociated in the same pressure range as dimers, trimers and
tetramers; ii) the primary sequence inﬂuences ﬁbril stability. In the
case ofα-synﬁbrils,wild type ﬁbrils aremore resistant toHHP than var-
iant ﬁbrils. This result has important physiological implications because
it suggests that the variantﬁbrils, which aremore labile,would generate
smaller toxic species more easily than wild type ﬁbrils. These ﬁndings
are consistent with the recently described model of the amyloid ﬁbril
[25] which showed that the ﬁbril core is dry, rendering the ﬁbrils sus-
ceptible to HHP, leading to further hydration of exposed side-chains
[68] (Fig. 6B).
Similar to α-syn, a disulﬁde-deﬁcient mutant of hen lysozyme is in-
trinsically unfolded and can form amyloid protoﬁbrils and ﬁbrils, which
are highly sensitive to pressure [34]. The authors showed the reversible
dissociation of multimeric precursors of the amyloid ﬁbrils of this pro-
tein. Overall, these studies indicate that hydrophobic interactions play
a crucial role in ﬁbril assembly and maintenance. HHP has emerged as
a promising tool for perturbing amyloid aggregates and for ﬁnding
new targets in the development of therapeutic compounds to block
ﬁbrillogenesis.
These data stimulated studies on the effects of physiologically and
therapeutically relevantmolecules to evaluate changes in ﬁbril stability.
We used the pressure approach to investigate how dopamine (DA)
Fig. 6. Fibrils derived from wild-type (wt) proteins (α-syn and TTR) have higher pres-
sure stability than ﬁbrils formed by variant proteins. A, Fibrils fromwt or mutant α-syn
[wt (squares); A53T (circles); A30P (triangles)] were subjected to increasing pressures
at 37 °C and disaggregation was followed by the decrease in light scattering (LS)
values. Isolated symbols on the left represent LS values obtained after return to
1 atm. B, Cavities present in the core of the ﬁbrils of wt TTR and α-syn render them
susceptible to HHP. Pressure (+p) stabilizes partially folded species (for wt TTR), or
native, unfolded monomers (for α-syn), as seen by tryptophan emission and bis-ANS
binding assays, allowing void volumes to be replaced by water.
Figure modiﬁed from reference [33].
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composed of wild-type or α-syn variants (A30P and A53T) [36].
When DA was absent, all α-syn protoﬁbrils exhibited identical levels
of stability against HHP; however, in the presence of DA, the variant
composed of protoﬁbrils was much more stable. This result implies
that α-syn protoﬁbrils last longer, offering a convincing explanation
as to why these mutations are so aggressive. When added to mesence-
phalic and cortical neurons in culture, A30P protoﬁbrils (PFA30P) and
A30P DA-protoﬁbrils (DAPFA30P) led to a signiﬁcant decrease in the
number and length of neurites and resulted in more cells undergoing
apoptosis. These toxic effects of PFA30P and DAPFA30Pwere practically
abolished by high-pressure treatment, which cracked the protoﬁbrils
into smaller aggregates, as visualized by atomic force microscopy [36].
These results suggest that strategies aimed at breaking and/or clearing
these aggregates may be promising in alleviating the symptoms of PD.
7. Conclusions and perspectives
Here we reviewed the studies performed in the last 15 years on
the effects of pressure on proteins involved in amyloid and protein
misfolding diseases. As expected, pressure treatment is a useful but
limited approach. In some cases, pressure induces the dissociation
of protoﬁbrils and ﬁbrils [4,33,37,51], but it fails to cause dissociationin several cases, as in the dissociation of short peptide segments of
TTR [92], β2-microglobulin [93], and islet amyloid polypeptide
[94]. In other cases, the population of folding intermediates created
by pressure leads to aggregation, e.g., p53 [66]. Several questions re-
main unsolved. We need to understand how the changes in packing
and cavity distribution change as the protein evolves to form small
oligomers, protoﬁbrils or protoﬁlaments and, ﬁnally, ﬁbrils. Pressure
is a strong tool to characterize these different intermediate species
[11,33,56,58,95]. This question is especially relevant in neurodegen-
erative disorders such as Parkinson's disease, prion diseases and
Alzheimer's disease, in which the massive destruction of neurons
takes place by a toxic gain-of-function. It is usually believed that
early pre-ﬁbrillar aggregates can be highly damaging to cells, where-
as mature ﬁbrils would be harmless [96–98]. The speciﬁc mecha-
nisms that explain these toxic effects are controversial. It is
possible that the “doughnut-like aggregates” make pores in mem-
branes, disrupting the ionic balance [96]. It is also possible that
such early aggregates, because they have hydrophobic segments
that are exposed to the environment, establish aberrant interactions
with membranes or other cellular components. All of these interac-
tions must be studied by high-pressure investigations.
The combination of pressure with structural and spectroscopic
tools is promising, and we should expect new discoveries in the
near future. The use of pressure to study p53C denaturation 10 years
ago allowed us to propose that the amyloid aggregation of p53, espe-
cially in the case of hot-spot mutants, could have a role in the patho-
physiology of malignant tumors. There is also potential to use HHP in
the high-throughput screening of compounds that affect the
folding-aggregation landscape of proteins involved in neurodegen-
erative diseases and cancer. As a general conclusion, HHP studies of
all of these interactions would yield unique and novel insights into
the mechanisms of amyloid formation.Acknowledgments
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